期刊文献+

罗格列酮联合胰岛素治疗老年肥胖2型糖尿病的临床观察

下载PDF
导出
摘要 目的观察罗格列酮对胰岛素治疗后血糖仍控制不佳的老年肥胖2型糖尿病患者的疗效和安全性。方法66例胰岛素治疗后血糖控制不佳的老年肥胖2型糖尿病患者随机分成罗格列酮组(R组)和对照组(C组)。C组单用胰岛素治疗并调整用量,R组加用罗格列酮4mg/d,随访12周,观察血糖、糖化血红蛋白、胰岛素用量等指标变化及药物不良反应。结果R组血糖水平从第2周起下降明显,至第8~12周下降幅度最大,有19例达到空腹血糖〈6.5mmol/L、餐后2h血糖〈8.0mmoVI.,的良好控制目标:从第2周开始,R组胰岛素用量也渐减少,至第12周时,R组胰岛素用量较基础值减少(7.7±4.4)U;而C组胰岛素用量平均增加(9.1±5.2)U。治疗后两组血糖、糖化血红蛋白和胰岛素用量比较差异有统计学意义。R组不良反应主要有轻度的低血糖及水肿。结论罗格列酮联合胰岛素治疗能确实有效控制老年肥胖2型糖尿病患者的血糖,治疗安全有效。
作者 覃保瑜 刘红
出处 《广西医学》 CAS 2006年第12期1907-1908,共2页 Guangxi Medical Journal
  • 相关文献

参考文献6

  • 1Lawrence LG. Rosiglitazone monotherapy and type 2 diabetes[J]. Diabet Meal,2001,18(suppl 4) :6-8.
  • 2Bretzel RG, Vovigt K, Sehatz H. The United Kingdom Prospective Diabetes Stady(UKPDS) implications for the pharmacotherapy of type 2diabetes mellitus[J ]. Exp Clin Endocrinol Diabetes, 1998,106(5 ) :369-372.
  • 3Half nor SM, Greenberg AS,Weston MW, et al. Effect of Rosiglitazone Treatment on Nontratlonal Markers of Cardiovascular Disease in Patiens With Type 2 Diabetes Mellitus [ J ]. Circulartion, 2002,106 (6) :679- 684.
  • 4王振基,申竹芳.噻唑烷二酮类不良反应研究进展[J].中国新药杂志,2005,14(11):1364-1366. 被引量:14
  • 5Bell DS.βcell rejuvenation with thiazolidinediones[J]. Am J Met,2003, 115(suppl 8A):20-30.
  • 6Mudaliar S, Chang AR, Henry RR. Tlliazolidinediones, peripheral edema,and type 2 diabetes: incidence, pathophysiology, and clinical implications[J].Endocr Pract. 2003,9(5) :406-416.

二级参考文献16

  • 1Ott P, Ranek L, Young MA. Pharmacokinetics of troglitazone, a PPAR-γ agonist, in patients with hepatic insufficiency[J]. Eur J Clin Pharmacol, 1998,54(7): 567 - 571.
  • 2Bonkovsky HL, Azar R, Bird S, et al. Severe cholestatic hepatitis caused by thiazolidinediones: risks associated with substituting rosiglitazone for troglitazone[J] . Dig Dis Sci ,2002, 47(7): 1632 -1637.
  • 3May LD, Lefkowitch JH, Kram MT, et al. Mixed hepatocellularcholestatic liver injury after pioglitazone therapy [ J ]. Ann Intern Med, 2002, 136(6): 449-452.
  • 4Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association [J]. Diabetes Care, 2004, 27(1):256-263.
  • 5Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in type 2 diabetic patients [ J ]. Diabetes Care,1999, 22(6) :908 - 912.
  • 6Song J, Knepper MA, Hu X, et al. Rosiglitazone activates renal sodium-and water-reabsorptive pathways and lower blood pressure in normal rats[J]. J Pharmacol Exp Ther, 2004, 308(2): 426 - 433.
  • 7Mudaliar S, Chang AR, Henry RR. Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications[J]. Endocr Pruct, 2003, 9(5): 406 - 416.
  • 8Buch HN, Baskar V, Barton DM, et al. Combination of insulin and thiazolidinedione therapy in massively obese patients with Type 2 diabetes[J]. Diabet Med, 2002,19(7): 572 - 574.
  • 9Lygate CA, Hulbert K, Monfared M, et al. The PPARgammaactivator rosiglitazone does not alter remodeling but increases mortality in rats post-myocardial infarction [ J ]. Cardiovasc Res,2003,58(3) :632 - 637.
  • 10Tan M, Johns D, Gonzalez GG, et al. Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized,double-blind, parallel-group trial [ J ]. Clin Ther, 2004, 26 ( 5 ):680 - 693.

共引文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部